Lilly's fourth-quarter financials beat Wall Street expectations, boosted by the successful launch of new weight-loss drug Zepbound and strong sales of diabetes treatment Mounjaro。The company reported adjusted earnings per share of 2.$49, well above analysts' expectations of 2.22 USD。Revenue reached 93.$500 million, more than expected 89.300 million dollars。

Zepbound, which was approved by U.S. regulators in early November, posted an impressive sales of 1 in the fourth quarter..$75.8 billion。That strong start puts Zepbound on track to surpass $1 billion in first-year sales and become the world's best-selling drug.。

Mounjaro is Eli Lilly's diabetes cure, further boosting Eli Lilly's revenue。Mounjaro sales soar to 22 in quarter.100 million U.S. dollars, up from 2 in the same period last year..$79.2 billion has increased significantly。The surge in sales reflects not only rising demand, but also Lilly's higher pricing strategy as it reduces its use of savings card plans。

Following these results, Lilly's stock jumped 5% in premarket trading。With a market capitalization of about $673 billion, the company is the largest pharmaceutical company in the United States.。Lilly's shares climbed nearly 60 percent last year, largely due to the increasing popularity of diet pills despite their high cost and inconsistent insurance coverage。

Eli Lilly will hold an earnings call with investors and is expected to have discussions around addressing its supply of diet pills and diabetes drugs.。In addition, investors are eagerly awaiting the latest decision from the U.S. Food and Drug Administration (FDA) on Lilly's experimental Alzheimer's drug, donanemab (donanemab)。

Lilly's market outlook is bullish in the near term, analysts say。Zepbound's successful IPO and Mounjaro's impressive revenues indicate strong market demand and effective pricing strategies。However, the company's ability to address supply constraints and the U.S. Food and Drug Administration's (FDA) decision on Donanib will be key to maintaining this positive momentum.。